On the latest episode of The Genetics Podcast, Patrick speaks with Max Bronstein, founder and CEO of Aviva Strategies, a health policy firm dedicated to support...
Continue reading
Genetic medicines have been advancing at an extraordinary pace. Following the first wave of adeno-associated virus (AAV)–based gene therapies, the toolbox for g...
Continue reading
The next generation of advanced therapies, particularly gene therapies, hold enormous promise for patients with rare conditions. However, their clinical develop...
Continue reading
In this week’s episode of The Genetics Podcast, we spoke with Richard Wilson, Senior Vice President and Primary Focus Lead for Genetic Regulation at Astellas, a...
Continue reading
Precision medicine trials increasingly depend on genetic or biomarker testing to determine eligibility. Each additional test introduces operational complexity: ...
Continue reading
In rare disease, families are often forced into roles that extend far beyond caregiving. When faced with diseases for which no treatment exists, parents have of...
Continue reading
Last week marked a major milestone for The Genetics Podcast: our 200th episode. To celebrate, host Patrick Short revisited some of the most impactful conversati...
Continue reading
In recent years, the therapeutic landscape for genetic hearing loss (GHL) has advanced rapidly, with several programs reaching clinical development. However, tr...
Continue reading
In the last episode of the Genetics Podcast, Patrick speaks with Dr. Xin Jin, a pioneering neuroscientist at Scripps Research, about her team’s cutting-edge met...
Continue reading
After a decade of strong investment, the biotech sector in 2025 is navigating a markedly constrained funding environment. Early-stage companies, particularly th...
Continue reading